New diabetes drug JY09 takes on dulaglutide in major trial
NCT ID NCT06257966
First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 35 times
Summary
This study compares two doses of a new drug, JY09, with the existing drug dulaglutide in 600 adults with type 2 diabetes whose blood sugar is not well controlled by metformin alone. The main goal is to see how well JY09 lowers blood sugar levels over 26 weeks. Participants will continue taking metformin and receive either JY09 or dulaglutide as an add-on treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.